These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

939 related items for PubMed ID: 19834322

  • 1. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH.
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [Abstract] [Full Text] [Related]

  • 2. Promising new approaches.
    Reasner CA.
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [Abstract] [Full Text] [Related]

  • 3. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 May; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 4. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL.
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [Abstract] [Full Text] [Related]

  • 5. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
    Niswender K.
    Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
    [Abstract] [Full Text] [Related]

  • 6. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 7. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ, McGill MA.
    Clin Drug Investig; 2012 Jan 01; 32(1):1-14. PubMed ID: 21958333
    [Abstract] [Full Text] [Related]

  • 8. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK.
    Ann Pharmacother; 2007 Jan 01; 41(1):51-60. PubMed ID: 17190843
    [Abstract] [Full Text] [Related]

  • 9. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B.
    Minerva Endocrinol; 2006 Jun 01; 31(2):133-47. PubMed ID: 16682937
    [Abstract] [Full Text] [Related]

  • 10. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M, Lam S.
    Cardiol Rev; 2007 Jun 01; 15(5):264-71. PubMed ID: 17700385
    [Abstract] [Full Text] [Related]

  • 11. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C, Bollaerts K.
    Int J Clin Pract Suppl; 2007 Aug 01; (154):29-37. PubMed ID: 17593275
    [Abstract] [Full Text] [Related]

  • 12. Protection of pancreatic beta-cells: is it feasible?
    Bonora E.
    Nutr Metab Cardiovasc Dis; 2008 Jan 01; 18(1):74-83. PubMed ID: 18096375
    [Abstract] [Full Text] [Related]

  • 13. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Jan 01; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 14. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
    Bonora E.
    Int J Clin Pract Suppl; 2007 Aug 01; (154):19-28. PubMed ID: 17593274
    [Abstract] [Full Text] [Related]

  • 15. Emergence of promising therapies in diabetes mellitus.
    Akkati S, Sam KG, Tungha G.
    J Clin Pharmacol; 2011 Jun 01; 51(6):796-804. PubMed ID: 20705952
    [Abstract] [Full Text] [Related]

  • 16. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects.
    Cefalu WT, Richards RJ, Melendez-Ramirez LY.
    Cleve Clin J Med; 2009 Dec 01; 76 Suppl 5():S39-47. PubMed ID: 19952302
    [Abstract] [Full Text] [Related]

  • 17. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G.
    Diabetes Obes Metab; 2007 Sep 01; 9 Suppl 1():32-9. PubMed ID: 17877545
    [Abstract] [Full Text] [Related]

  • 18. The importance of beta-cell management in type 2 diabetes.
    Standl E.
    Int J Clin Pract Suppl; 2007 Jun 01; (153):10-9. PubMed ID: 17594389
    [Abstract] [Full Text] [Related]

  • 19. Incretin-based therapy and type 2 diabetes.
    Hare KJ, Knop FK.
    Vitam Horm; 2010 Jun 01; 84():389-413. PubMed ID: 21094909
    [Abstract] [Full Text] [Related]

  • 20. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
    Kruger DF.
    Diabetes Educ; 2008 Jun 01; 34 Suppl 3():60S-65S. PubMed ID: 18525066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.